GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » Equity-to-Asset

TME Pharma NV (XPAR:ALTME) Equity-to-Asset : -0.12 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. TME Pharma NV's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €-0.29 Mil. TME Pharma NV's Total Assets for the quarter that ended in Dec. 2023 was €2.49 Mil.

The historical rank and industry rank for TME Pharma NV's Equity-to-Asset or its related term are showing as below:

XPAR:ALTME' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.21   Med: -0.72   Max: 0.72
Current: -0.12

During the past 10 years, the highest Equity to Asset Ratio of TME Pharma NV was 0.72. The lowest was -4.21. And the median was -0.72.

XPAR:ALTME's Equity-to-Asset is ranked worse than
86.07% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs XPAR:ALTME: -0.12

TME Pharma NV Equity-to-Asset Historical Data

The historical data trend for TME Pharma NV's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Equity-to-Asset Chart

TME Pharma NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.06 0.72 0.46 -0.24 -0.12

TME Pharma NV Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.27 -0.24 -0.05 -0.12

Competitive Comparison of TME Pharma NV's Equity-to-Asset

For the Biotechnology subindustry, TME Pharma NV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TME Pharma NV's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's Equity-to-Asset falls into.



TME Pharma NV Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

TME Pharma NV's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-0.294/2.491
=

TME Pharma NV's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-0.294/2.491
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TME Pharma NV  (XPAR:ALTME) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


TME Pharma NV Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


TME Pharma NV (XPAR:ALTME) Business Description

Traded in Other Exchanges
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines